Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

CEO

Mr. Donald J. McCaffrey

Employees

Country

Canada

ISIN

CA76128M1086

Listings

0 Comments

Share your thoughts

FAQ

What is Resverlogix stock price today?▼

The current price of RFS.STU is €0.06 EUR — it has increased by +0% in the past 24 hours. Watch Resverlogix stock price performance more closely on the chart.

What is Resverlogix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Resverlogix stocks are traded under the ticker RFS.STU.

Is Resverlogix stock price growing?▼

RFS.STU stock has risen by +5.26% compared to the previous week, the month change is a -16.67% fall, over the last year Resverlogix has showed a +155.32% increase.

How many employees does Resverlogix have?▼

As of April 15, 2026, the company has 19 employees.

In which sector is Resverlogix located?▼

Resverlogix operates in the Health & Wellness sector.

When did Resverlogix complete a stock split?▼

Resverlogix has not had any recent stock splits.

Where is Resverlogix headquartered?▼

Resverlogix is headquartered in Calgary, Canada.